Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
Where Empathy Meets Compassion: Championing Alzheimer’s Awareness
This World Alzheimer's Day, doctors, patients and their caregivers gathered for an…
Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94%…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres
Broadened indication increases access to liver cancer treatment across Europe and CE-marked…
KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025
RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist…
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Medidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience Forward
Medidata eCOA was the highest Leader recognized in the evaluation, supporting over…
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,…
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq:…